Updated:
CytomX Therapeutics
CytomX Therapeutics launched in 2010, founded by Nancy Stagliano and Henry Lowman with scientific roots in the laboratory of Patrick Daugherty at UC Santa...
CytomX Therapeutics
CytomX Therapeutics launched in 2010, founded by Nancy Stagliano and Henry Lowman with scientific roots in the laboratory of Patrick Daugherty at UC Santa Barbara. The firm's core technology — Probody® — uses peptides to mask antibody binding sites, activating only in the tumor microenvironment. This approach targeted a central oncology problem: on-target, off-tumor toxicity that constrains dosing for otherwise potent antibodies. Sean McCarthy, a veteran of Millennium Pharmaceuticals, was brought in as CEO early to translate the academic work into a drug pipeline. The firm's strategy channels capital into proprietary masked immunotherapies, spanning immuno-oncology, antibody-drug conjugates, and T-cell engagers. Its lead asset, CX-2009, a CD166-directed ADC, showed monotherapy responses in hormone receptor-positive breast cancer during Phase I, leading to a partnership with AbbVie on CD71-targeted conjugates. A marquee collaboration with Bristol Myers Squibb, signed in 2014 and significantly expanded in 2017, focused on CTLA-4-targeted probody ipilimumab (BMS-986249) — demonstrating preclinical tumor-selective activation. Additional partnerships materialized with Amgen on a CytomX-derived bispecific T-cell engager and with Astellas on T-cell engaging bispecifics, deploying the Probody platform across North America and Asia-Pacific territories. CytomX filed its IPO in 2015 on NASDAQ under ticker CTMX, raising $80M after a decade of private financing totaling over $400M from backers including Canaan Partners, Venrock, and Fidelity. In May 2024, the firm announced a corporate restructuring that reduced its workforce by approximately 40% and narrowed its pipeline focus entirely to its clinical-stage assets — most notably CX-2051, an EpCAM-directed ADC in Phase I for advanced solid tumors, and CX-904, a conditionally activated EGFRxCD3 bispecific partnered with Amgen. The company also terminated its internal CX-2028 program and eliminated discovery research to extend cash runway into late 2026. The firm's structural differentiator is its clinical-stage masking technology, which attempts to convert systemic immunotherapy into a localized event. Unlike conventional oncology platforms that rely on tumor-specific antigens, CytomX's approach harnesses dysregulated protease activity in the tumor microenvironment to unmask antibody function. This architecture allows the company to target validated, broadly expressed antigens — such as EpCAM or CD71 — that are otherwise pharmacologically inaccessible due to normal-tissue toxicity, creating a pipeline built on validated biology rather than novel targets.
General information
Firm type
Asset Manager
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
South San Francisco
Corporate office
South San Francisco, CA, United States
Principals
Sean McCarthy
Chief Executive Officer
Sector focus
Frequently asked questions
How does CytomX's Probody platform differ from standard antibody therapeutics?
The Probody platform uses a peptide mask to block the antibody's antigen-binding site, rendering it inactive in circulation and healthy tissue. The mask is cleaved by dysregulated proteases present in the tumor microenvironment, restoring antibody function locally. This design allows CytomX to target antigens like EpCAM and CD71 that are broadly expressed on normal tissues but overexpressed in tumors — targets that would otherwise cause severe on-target, off-tumor toxicity with a conventional antibody.
What is CytomX's pipeline status after the May 2024 restructuring?
The May 2024 restructuring eliminated internal discovery research and terminated the CX-2028 program. The company now focuses on two clinical-stage assets: CX-2051, an EpCAM-directed antibody-drug conjugate in a Phase I dose-escalation trial for advanced solid tumors, and CX-904, an EGFRxCD3 T-cell engaging bispecific partnered with Amgen and in early clinical testing. The restructuring extended cash runway into late 2026.
Which pharmaceutical partners has CytomX worked with?
CytomX has entered partnerships with Bristol Myers Squibb on a Probody version of ipilimumab (BMS-986249), with AbbVie on CD71-directed antibody-drug conjugates, with Amgen on CX-904 and a broader bispecific collaboration, and with Astellas on T-cell engaging bispecifics. The BMS collaboration was initially signed in 2014 and expanded in 2017 with $200 million in upfront payments.
Who runs investment decisions at CytomX?
CytomX Therapeutics is a public biotechnology company, not an investment firm. Capital allocation decisions are made by the executive team under CEO Sean McCarthy and overseen by the board of directors. Allocation priorities are dictated by pipeline stage-gating, partnership economics, and cash-runway management — a stated priority since the May 2024 restructuring.
Is CytomX structured as an investment fund or an operating company?
CytomX Therapeutics is a publicly traded operating company listed on NASDAQ under ticker CTMX. It develops drug candidates internally and through pharma partnerships. Though the name was input with a family-office classification, CytomX is a clinical-stage biotechnology company that raised venture capital from 2010 to 2015 before its IPO.
How does CytomX source capital for its operations?
Since its 2015 IPO, CytomX has funded operations through a combination of equity financings, partnership upfront payments, milestone payments, and royalties. Pre-IPO investors include Canaan Partners, Venrock, and Fidelity. The company has not disclosed private-market fundraising since becoming a public entity, relying instead on partnership economics and occasional public offerings.
What is CytomX's known posture on clinical-stage risk?
CytomX accepts late-preclinical and clinical-stage risk as part of its operating model. The Probody platform introduces an additional pharmacological variable — protease-cleavable masking — that introduces both clinical differentiation and uncertainty relative to conventional antibodies. The May 2024 restructuring, which eliminated discovery research, signals a prioritization of nearer-term clinical readouts over platform expansion.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: